病毒性重症肝炎(以下简称重症肝炎)的抢救治疗仍然是个棘手的问题,我院以往采用中西医综合抢救措施,但存活率仅20～40％。自1983年起,在中西医综合治疗的基础上,加用山莨菪硷静脉滴注,至1984年底,共治疗重症肝炎114例(治疗组),疗效明显提高,存活率提高至59％,现分析如下。一、病例选择及分型:本组病例均符合1978年全国肝炎杭州会议制订的诊断标准。各组的病型见表2。二、治疗方法:分治疗组(114例)和对照组(1)(45例),对照组(2)(56例)。治疗组采用中西医综合疗法(包括保肝、支持疗法、中药、抗感染、部分病例使用激素)加山莨菪硷静滴。一般用山莨菪 The treatment of viral severe hepatitis (hereinafter referred to as severe hepatitis) is still a thorny problem. In our hospital, we used the integrated Chinese and Western remedies in the past, but the survival rate was only 20-40%. Since 1983, on the basis of comprehensive treatment of traditional Chinese and Western medicine, plus anisodamine intravenous infusion, to the end of 1984, a total of 114 cases of severe hepatitis treatment (treatment group), the therapeutic effect was significantly improved, the survival rate increased to 59%, and now analyse as below. First, the case selection and typing: This group of patients are in line with the 1978 National Hepatitis Hangzhou meeting the diagnostic criteria. The types of each group in Table 2. Second, treatment: sub-treatment group (114 cases) and control group (1) (45 cases), control group (2) (56 cases). Treatment group using integrated traditional Chinese and Western medicine (including liver, supportive therapy, traditional Chinese medicine, anti-infective, in some cases the use of hormones) plus anisodamine intravenous infusion. Anisodus commonly used